Approaches towards menstrual cycle disorder therapy in reproductive-aged women with long COVID

Authors

  • V.V. Kaminskyi P.L. Shupyk National University of Health of Ukraine; Kyiv City Center of Reproductive and Perinatal Medicine, Kyiv, Ukraine http://orcid.org/0000-0002-5369-5817
  • A.V. Serbeniuk Ukrainian State Institute of Reproductology, P.L. Shupyk National University of Health of Ukraine; Clinic of Reproductive Technologies, Ukrainian State Institute of Reproductology, P.L. Shupyk National University of Health of Ukraine, Kyiv, Ukraine https://orcid.org/0000-0002-7212-2678
  • Y.O. Kumpanenko P.L. Shupyk National Healthcare University of Ukraine; Kyiv City Center of Reproductive and Perinatal Medicine, Kyiv, Ukraine https://orcid.org/0000-0002-7019-5662

DOI:

https://doi.org/10.18370/2309-4117.2023.68.44-47

Keywords:

long COVID, reproductive health, premenstrual syndrome, gastrointestinal tract

Abstract

Background. The mirror of a female’s reproductive health is the menstrual cycle. The SARS-CoV-2 pandemic itself acts as a significant stressor. This leads to women’s overall health and life quality disturbance. Moreover, patients struggle with long COVID effects, which is a prolongation of symptoms after recovery. Due to the expression of angiotensin-converting enzyme type 2 receptors in the intestinal mucosa and inflammation, the gastrointestinal (GI) tract is also triggered by the virus.
Objectives. To assess the efficacy of the chosen treatment approach in women with changes in premenstrual syndrome and cyclicity due to long COVID with or without GI symptoms.
Material and methods. A single-centre longitudinal interventional study was organized. Were studied data from the conducted tests (progesterone level, ultrasound follicle scan, etc.) and surveys. Then the effectiveness of the suggested treatment with the use of oral and vaginal forms of progesterone was evaluated. The study was held in the Kyiv City Center of Reproductive and Perinatal Medicine (Ukraine) from January to June 2021.
Results. On average 78% patients without GI symptoms experienced relief after 3 months and 89% patients after 6 months of suggested treatment. 71% patients with GI symptoms experienced improvement after 3 and 87% of them after 6 months. The vaginal progesterone had better results compared to oral form. Averagely 6–8% experienced side effects (nausea, hypotension, less compliance) due to progesterone intake. The vaginal micronised progesterone also presented better results than oral with fewer side effects compared to the total number of participants.
Conclusions. The proposed approach has shown particular correction of the menstrual cycle disturbances in women with long COVID. Vaginal micronized progesterone offers more promising outcomes in patients with GI symptoms and disrupted absorption, compared to the oral form.
Further investigation is required for a more reasonable conclusion.

Author Biographies

V.V. Kaminskyi, P.L. Shupyk National University of Health of Ukraine; Kyiv City Center of Reproductive and Perinatal Medicine, Kyiv

Academician of the NAMS of Ukraine, MD, professor, head of the Obstetrics, Gynecology and Reproductology Department;
Head

A.V. Serbeniuk, Ukrainian State Institute of Reproductology, P.L. Shupyk National University of Health of Ukraine; Clinic of Reproductive Technologies, Ukrainian State Institute of Reproductology, P.L. Shupyk National University of Health of Ukraine, Kyiv

PhD, assistant, Obstetrics, Gynecology and Reproductology Department;
Obstetriciangynecologist

Y.O. Kumpanenko, P.L. Shupyk National Healthcare University of Ukraine; Kyiv City Center of Reproductive and Perinatal Medicine, Kyiv

Graduate student, Obstetrics, Gynecology and Reproductology Department; 
Obstetrician-gynecologist

References

  1. Islam, M.A., Kundu, S., Alam, S.S., et al. “Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients.” PLoS One 16.4 (2021): e0249788. DOI: 10.1371/journal.pone.0249788. PMID: 33822812; PMCID: PMC8023501.
  2. Islam, M.A., Alam, S.S., Kundu, S., et al. “Prevalence of Headache in Patients With Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of 14,275 Patients.” Front Neurol 11 (2020): 562634. DOI: 10.3389/fneur.2020.562634. PMID: 33329305; PMCID: PMC7728918.
  3. Koh, J., Shah, S.U., Chua, P.E.Y., et al. “Epidemiological and Clinical Characteristics of Cases During the Early Phase of COVID-19 Pandemic: A Systematic Review and Meta-Analysis.” Front Med 7 (2020): 295. DOI: 10.3389/fmed.2020.00295
  4. Hu, Y., Sun, J.Z., Dai, Z., et al. “Prevalence and severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.” J Clin Virol 127 (2020): 104371. DOI: 10.1016/j.jcv.2020.104371
  5. Grant, M.C., Geoghegan, L., Arbyn, M., et al. “The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries.” Plos One 15.6 (2020): e0234765. DOI: 10.1371/journal.pone.0234765
  6. Han, C.Q., Duan, C.H., Zhang, S.Y., et al. “Digestive Symptoms in COVID-19 Patients with Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes.” Am J Gastroenterol 115.6 (2020): 916–23. DOI: 10.14309/ajg.0000000000000664
  7. Yan, R.H., Zhang, Y.Y., Li, Y.N., et al. “Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.” Science 367.6485 (2020): 1444–8. DOI: 10.1126/science.abb2762
  8. Tian, Y., Rong, L., Nian, W.D., He, Y. “Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission.” Aliment Pharmacol Ther 51.9 (2020): 843–51. DOI: 10.1111/apt.15731
  9. Sajdel-Sulkowska, E.M. “A Dual-Route Perspective of SARS-CoV-2 Infection: Lung- vs. Gut-specific Effects of ACE-2 Deficiency.” Front Pharmacol 12 (2021): 684610. DOI: 10.3389/fphar.2021.684610
  10. de Olieveira, A.P., Lopes, A.L.F., Pacheco, G., et al. “Premises among SARS-CoV-2, dysbiosis and diarrhea: Walking through the ACE2/mTOR/autophagy route.” Medical Hypotheses 144 (2020). DOI: 10.1016/j.mehy.2020.110243
  11. Greenhalgh, T., Knight, M., A’Court, C., et al. “Management of post-acute covid-19 in primary care.” BMJ 370 (2020). DOI: 10.1136/bmj.m3026
  12. Tenforde, M.W., Kim, S.S., Lindsell, C.J., et al. “Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network – United States, March–June 2020.” MMWR Morb Mortal Wkly Rep 69 (2020): 993–8. DOI: 10.15585/mmwr.mm6930e1
  13. Carfì, A., Bernabei, R., Landi, F.; Gemelli Against COVID-19 Post- Acute Care Study Group. “Persistent Symptoms in Patients After Acute COVID-19.” JAMA 324.6 (2020): 603–5. DOI: 10.1001/jama.2020.12603
  14. Fernandez-de-las-Penas, C., Palacios-Cena, D., Gomez- Mayordomo, V., et al. “Defining Post-COVID Symptoms (Post-Acute COVID, Long COVID, Persistent Post-COVID): An Integrative Classification.” Int J Environ Res Public Health 18.5 (2021): 2621. DOI: 10.3390/ijerph18052621
  15. Li, K.Z., Chen, G., Hou, H.Y., et al. “Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age.” Reprod Biomed Online 42.1 (2021): 260–7. DOI: 10.1016/j.rbmo.2020.09.020
  16. Kala, M., Nivsarkar, M. “Role of cortisol and superoxide dismutase in psychological stress- induced anovulation.” Gen Comp Endocrinol 225 (2016): 117–24. DOI: 10.1016/j.ygcen.2015.09.010
  17. Callachan, H., Cottrell, G.A., Hather, N.Y., et al. “Modulation of the GABAA receptor by progesterone metabolites.” Proc R Soc Lond B Biol Sci 231.1264 (1987): 359–69. DOI:10.1098/rspb.1987.0049
  18. Rees, L. “The premenstrual tension syndrome and its treatment.” BMJ 1.4818 (1953): 1014–6. DOI: 10.1136/bmj.1.4818.1014
  19. Maher, M., O’Keeffe, A., Phelan, N., et al. “Female Reproductive Health Disturbance Experienced During the COVID-19 Pandemic Correlates with Mental Health Disturbance and Sleep Quality.” Front Endocrinol 13 (2022): 838886. DOI: 10.3389/fendo.2022.838886
  20. Demir, O., Sal, H., Comba, C. “Triangle of COVID, anxiety and menstrual cycle.” J Obstet Gynaecol 41.8 (2021): 1257–61. DOI: 10.1080/01443615.2021.1907562
  21. Phelan, N., Behan, L.A., Owens, L. “The Impact of the COVID-19 Pandemic on Women’s Reproductive Health.” Front Endocrinol 12 (2021): 642755. DOI: 10.3389/fendo.2021.642755
  22. Peng, E.Y.C., Lee, M.B., Tsai, S.T., et al. “Population-based Post-crisis Psychological Distress: An Example from the SARS Outbreak in Taiwan.” J Formos Med Assoc 109.7 (2010): 524–32. DOI: 10.1016/s0929-6646(10)60087-3
  23. Irwin, R.W., Solinsky, C.M., Brinton, R.D. “Frontiers in therapeutic development of allopregnanolone for Alzheimer’s disease and other neurological disorders.” Front Cell Neurosci 8 (2014): 203. DOI: 10.3389/fncel.2014.00203
  24. Groff, A., Kavanaugh, M., Ramgobin, D., et al. “Gastrointestinal Manifestations of COVID-19: A Review of What We Know.” Ochsner J 21.2 (2021): 177–80. DOI: 10.31486/toj.20.0086
  25. Shanka, M.S., Kotecho, M.G. “Combining rationality with morality-integrating theory of planned behavior with norm activation theory to explain compliance with COVID-19 prevention guidelines.” Psychol Health Med (2021): 1–11. DOI: 10.1080/13548506.2021.1946571

Downloads

Published

2023-06-30

How to Cite

Kaminskyi, V., Serbeniuk, A., & Kumpanenko, Y. (2023). Approaches towards menstrual cycle disorder therapy in reproductive-aged women with long COVID. REPRODUCTIVE ENDOCRINOLOGY, (68), 44–47. https://doi.org/10.18370/2309-4117.2023.68.44-47

Issue

No. 68 (2023)

Section

Gynecology

License

Copyright (c) 2023 В.В. Камінський, A.V. Serbeniuk, Я.О. Кумпаненко

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.